Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 6/20 | 0.45 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.39 |
| ▸ | DTYMK | P23919 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20324790 | 1.00 | STING1 (0.45) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20324793 | 0.95 | FUT5 (0.47) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20324901 | 0.95 | FUT5 (0.47) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20327217 | 0.92 | POLB (0.47) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20326986 | 0.90 | STING1 (0.44) | STING1FUT5NT5EPOLBTGM2 | |
| SCHEMBL20326944 | 0.89 | FUT5 (0.48) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL22524137 | 0.89 | FUT5 (0.48) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20324791 | 0.89 | POLB (0.47) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20327546 | 0.88 | STING1 (0.48) | STING1FUT5NT5EPOLBF2 | |
| SCHEMBL20324898 | 0.88 | STING1 (0.48) | STING1FUT5NT5EPOLBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |